Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
The Troglitazone study group, Sudhesh Kumar, A. J. M. Boulton et al. · Diabetologia · 1996
Cited by 236 works. doi:10.1007/bf00418542
Authors
- Sudhesh Kumar
- A. J. M. Boulton
- Henning Beck‐Nielsen
- F Berthezène
- Michele Muggeo
- Bertil Persson
- Giatgen A. Spinas
- Stephen Donoghue
- Sally Lettis
- P. Stewart-Long
References
- Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
- Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
- The Design and Analysis of Clinical Experiments
- The Design and Analysis of Clinical Experiments.
- An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)
- Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease
- Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
- Pathogenesis of NIDDM: A Balanced Overview
- Critical Variables in the Radioimmunoassay of Serum Insulin Using the Double Antibody Technic